Try our Advanced Search for more refined results

In Re: National Prescription Opiate Litigation

Track this case

Case overview

Case Number:

1:17-md-02804

Court:

Ohio Northern

Nature of Suit:

P.I.: Other

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

Dan Aaron Polster (MDL 28

Firms

Companies

Government Agencies

Sectors & Industries:

  1. June 21, 2019

    Biggest Health And Life Sci Rulings Of 2019: Midyear Report

    The first half of 2019 saw an extraordinary eruption of important court decisions likely to leave lasting marks on the opioid crisis, the False Claims Act, the Affordable Care Act and Medicare reimbursement. Here, Law360 takes stock of consequential health care and life sciences rulings that lawyers need to know.

  2. June 14, 2019

    3 Takeaways As 'Negotiation Class' Idea Jolts Opioid MDL

    An unconventional move Friday to resolve multidistrict opioid litigation by unifying local governments in a “negotiation class” could be an inflection point for the bruising legal slugfest targeting drug companies, although class certification isn’t a sure thing. Here, Law360 explores three key takeaways from the high-stakes maneuver.

  3. June 14, 2019

    'Negotiation Class' May Tee Up Sweeping Deal In Opioid MDL

    Local governments in the multidistrict opioid litigation on Friday launched an unusual effort to create a "negotiation class" of cities and counties that would seek a global settlement with drug companies accused of igniting a nationwide firestorm of addiction.

  4. June 12, 2019

    Shoshone Tribe Joins Opioid MDL, Details Epidemic's Impact

    The Eastern Shoshone Tribe announced on Tuesday that it is joining a national multidistrict litigation seeking to hold pharmaceutical companies responsible for the country's opioid epidemic, alleging that the drugs have hit Native American nations particularly hard.

  5. May 08, 2019

    BakerHostetler Fights 'Indefensible' DQ In Opioid MDL

    BakerHostetler on Wednesday asked the Sixth Circuit to vacate an Ohio judge's decision to disqualify the firm from representing Endo Pharmaceuticals in two bellwether cases in the multidistrict opioid litigation, saying the decision will affect the entire MDL.

  6. April 26, 2019

    Atty Sanctions Axed In Opioid MDL, Allowing Doc's Testimony

    An Ohio federal judge on Friday scrapped attorney sanctions that would have barred testimony from a high-profile pain doctor in the multidistrict opioid litigation, calling the discipline "too extreme" despite a galling failure by plaintiffs' attorneys to divulge a deal with the doctor.

  7. April 25, 2019

    Opioid MDL Attys' Concealment Merited Sanction: Drug Cos.

    Plaintiffs' attorneys who hid key witness testimony in the multidistrict opioid litigation were properly sanctioned by having that testimony blocked from a bellwether trial, drug companies told an Ohio federal court on Thursday.

  8. April 18, 2019

    Postpone Opioid MDL Trial? Get Real, Judge Says

    An Ohio federal judge on Thursday said that drug companies in the multidistrict opioid litigation are apparently maneuvering to indefinitely delay a bellwether trial and that the idea isn't even worthy of consideration.

  9. April 16, 2019

    Opioid MDL Attys Say Sanction 'Does Not Fit The Crime'

    Plaintiffs attorneys in the multidistrict opioid litigation are contesting a sanction that would block testimony from an influential doctor whose cooperation they failed to disclose, calling it "a punishment that does not fit the crime."

  10. April 10, 2019

    No More Trial Delays In Opioid MDL, Judge Says

    An Ohio federal judge on Wednesday declared that a highly anticipated bellwether trial in the multidistrict opioid litigation won't be postponed again, a move that follows delays and allegations that the drug companies are stalling.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!